News

Corcept Therapeutics announced results from its Phase 2 DAZALS study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS)....

CatalYm’s lead drug candidate, visugromab, a monoclonal antibody targeting the immunosuppressant GDF-15, has shown promising results in a Phase...

Spruce Biosciences announced topline results from two clinical trials, CAHmelia-204 and CAHptain-205, evaluating tildacerfont for congenital adrenal hyperplasia (CAH)....

City of Hope researchers presented groundbreaking studies at the 2024 ASH conference, focusing on innovative treatments for various blood...

Incyte announced positive Phase 3 inMIND trial results for tafasitamab combined with lenalidomide and rituximab in relapsed or refractory...

The Phase 3 inMIND trial showed positive results for tafasitamab combined with lenalidomide and rituximab in treating relapsed or...

Acticor Biotech, a clinical-stage biopharmaceutical company developing glenzocimab for cardiovascular emergencies, faces liquidation as the court-appointed administrator has requested...

BeiGene, soon to be BeOne Medicines, presented positive clinical data for BRUKINSA (zanubrutinib) and other pipeline assets in chronic...

Bristol Myers Squibb (BMS) presented 18 analyses at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing the...

A five-year follow-up analysis of the ZUMA-5 Phase 2 study shows promising results for Yescarta (axicabtagene ciloleucel) in patients...